SCHEMBL19915872

SCHEMBL19915872

FC(F)(F)c1ccc2c(c1)nnn2-c1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.56
▸ KCNMA1 Q12791 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ KIF11 P52732 1/20 0.41
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SRC P12931 1/20 0.36
▸ BRAF P15056 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ PDE10A Q9Y233 2/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ PDE7A Q13946 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848320 0.88 L3MBTL1 (0.46) PKMKCNMA1L3MBTL1MAPTRAB9A
SCHEMBL19848254 0.86 L3MBTL1 (0.60) PKMKCNMA1L3MBTL1MAPTRAB9A
SCHEMBL19911611 0.80 ALDH1A1 (0.49) KCNMA1L3MBTL1ALDH1A1KDM4ENPC1
SCHEMBL19911580 0.76 NPC1 (0.73) L3MBTL1MAPTRAB9AALDH1A1KDM4E
SCHEMBL19848242 0.76 ALDH1A1 (0.49) KCNMA1L3MBTL1ALDH1A1KDM4ENPC1
SCHEMBL19915941 0.74 L3MBTL1 (0.50) PKMKCNMA1L3MBTL1MAPTRAB9A
SCHEMBL19848381 0.74 HPGD (0.52) PKMMAPTRAB9AALDH1A1KDM4E
SCHEMBL19848195 0.73 ALDH1A1 (0.45) L3MBTL1MAPTRAB9AALDH1A1KDM4E
SCHEMBL13016550 0.72 PKM (0.65) PKMKCNMA1MAPTRAB9AALDH1A1
SCHEMBL19848261 0.72 PKM (0.65) PKMKCNMA1L3MBTL1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 — — US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 — — EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 PKM 2292/4885KCNMA1 525/4885L3MBTL1 2127/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 PKM 2292/4885KCNMA1 525/4885L3MBTL1 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback